Replimune Group (NASDAQ:REPL) Upgraded to “Strong-Buy” at Piper Sandler

Piper Sandler upgraded shares of Replimune Group (NASDAQ:REPL) from a hold rating to a strong-buy rating in a report released on Friday morning,Zacks.com reports.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Tuesday, June 30th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $9.29.

Replimune Group Stock Up 107.0%

NASDAQ:REPL opened at $11.20 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The company’s fifty day moving average price is $9.49 and its 200-day moving average price is $7.38. Replimune Group has a 1-year low of $1.50 and a 1-year high of $12.50. The firm has a market capitalization of $941.14 million, a P/E ratio of -3.31 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts anticipate that Replimune Group will post -2.44 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. increased its position in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Replimune Group during the 4th quarter worth $17,568,000. Commodore Capital LP purchased a new stake in shares of Replimune Group during the fourth quarter worth $13,851,000. EcoR1 Capital LLC acquired a new stake in shares of Replimune Group in the first quarter valued at about $7,650,000. Finally, JPMorgan Chase & Co. raised its position in shares of Replimune Group by 2,333.6% in the fourth quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock valued at $8,993,000 after buying an additional 887,157 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee backed results from the IGNYTE trial of RP1 (vusolimogene oderparepvec) combined with nivolumab for advanced melanoma patients whose disease progressed after anti-PD-1 therapy. The panel considered the evidence and clinical benefit meaningful despite concerns about the trial design. Replimune surges after FDA advisers back skin cancer drug
• Positive Sentiment: The 10-3 vote was widely viewed as a favorable regulatory signal, with analysts describing the panel outcome as overwhelmingly positive and suggesting that RP1’s approval prospects have improved. REPL Stock Tracks Best Day Ever
• Positive Sentiment: Replimune formally announced the favorable committee outcome for its resubmitted Biologics License Application, giving investors a clearer path toward a potential commercial product. Replimune Announces Favorable Outcome of FDA Advisory Committee Meeting

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.